Takashi Hayakawa, Hayato Akimoto, Takuya Nagashima, Kimino Minagawa, Yasuo Takahashi, Satoshi Asai. Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records. BMC Pharmacology and Toxicology. 2025. 26. 1
Hayato Akimoto, Takuya Nagashima, Kimino Minagawa, Takashi Hayakawa, Yasuo Takahashi, Satoshi Asai. Non-Linear Dose-Response Relationship for Metformin in Japanese Patients With Type 2 Diabetes: Analysis of Irregular Longitudinal Data by Interpretable Machine Learning Models. Pharmacology Research & Perspectives. 2025. 13. 1
Yasuo Takahashi, Kimino Minagawa, Takuya Nagashima, Takashi Hayakawa, Hayato Akimoto, Satoshi Asai. Long-term benefit of SGLT2 inhibitors to prevent heart failure hospitalization in patients with diabetes, with potential time-varying benefit. Clinical and Translational Science. 2024. 17. 12
Kimino Minagawa, Takashi Hayakawa, Hayato Akimoto, Takuya Nagashima, Yasuo Takahashi, Satoshi Asai. Late development of OCD-like phenotypes in Dlgap1 knockout mice. Psychopharmacology. 2024
Takashi Hayakawa, Takuya Nagashima, Hayato Akimoto, Kimino Minagawa, Yasuo Takahashi, Satoshi Asai. Benzodiazepine-related dementia risks and protopathic biases revealed by multiple-kernel learning with electronic medical records. DIGITAL HEALTH. 2023. 9. 205520762311785
An early and versatile detection scheme of adverse drug reactions using large-scale administrative claims data
(第96回日本薬理学会年会 2022)
Identifying antidepressants less likely to cause hyponatremia: triangulation of retrospective cohort, disproportionality, and pharmacodynamic studies
(第96回日本薬理学会年会 2022)
Identification of the therapeutic target for tendinopathy through the combination of real world data analysis and pharmacological experiments
(第96回日本薬理学会年会 2022)
